Clinical Trial Update: Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis [Phase 2]

View source ↗

Summary

A Phase 2 trial investigates an alternative dosing strategy for ruxolitinib in myelofibrosis, with completed results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis
• Post-essential Thrombocythemia Myelofibrosis
• Post-polycythemia Vera Myelofibrosis

Drugs mentioned

• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Incyte Corporation | Conditions: Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis | Phase 2 | Status: COMPLETED | Results posted: 2014-09-19